US › Healthcare

Citius Pharmaceuticals Inc (CTXR)

US · Healthcare · Biotechnology

$0.62+4.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.7M
Net profit
$-21.2M
Profit YoY
-94.5%
EPS
$-0.95
EPS estimate
$-0.32
Net margin
-1,273.4%

EPS came in at -0.95 against a street estimate of -0.32 — a miss of 196.9%.

Key statistics

Market cap
$15.6M
Forward P/E
0.3
P/B
0.25
Book value
$2.75
EPS (TTM)
$-2.14
52-week high
$2.19
52-week low
$0.47
50-day MA
$0.57
200-day MA
$0.86
Beta
0.98

Analyst view

Analysts rate Citius Pharmaceuticals Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $4.00.

Shareholding

Insiders
1.80%
Institutions
4.16%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.90%
Vanguard Capital Management, LLC0.61%
Vanguard Fiduciary Trust Co0.28%
BlackRock Inc0.25%
HRT FINANCIAL LLC0.22%
Asset Advisory Group, INC.0.21%
UBS Group AG0.20%
Northern Trust Corp0.16%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Citius Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.